S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study
Frans J. Th. Wackers,Deborah Chyun,Lawrence H. Young,Gary V. Heller,Ami E. Iskandrian,Janice A. Davey,Eugene J. Barrett,Raymond Taillefer,Steven D. Wittlin,Neil Filipchuk,Robert E. Ratner,Silvio E. Inzucchi +11 more
TL;DR: In this paper, the authors assessed whether the prevalence of inducible myocardial ischemia increases over time in patients with type 2 diabetes and found that patients with resolution of ischemies had significantly greater increases in these medications than patients who developed new ischemias (P = 0.04).
Journal ArticleDOI
"Glucometrics"—Assessing the Quality of Inpatient Glucose Management
Philip A. Goldberg,Janis Bozzo,Prem Thomas,Melinda M Mesmer,Olga V. Sakharova,Martha J. Radford,Silvio E. Inzucchi +6 more
TL;DR: Of the three models tested, the patient-day model appears to most faithfully reflect the quality of inpatient glycemic control, and achieving 85% of BG levels within optimal range may be considered gold standard.
Journal ArticleDOI
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Bernard Zinman,Silvio E. Inzucchi,John M. Lachin,Christoph Wanner,David Fitchett,Sven Kohler,Michaela Mattheus,Hans J. Woerle,Uli C. Broedl,Odd Erik Johansen,Gregory W. Albers,Hans-Christoph Diener +11 more
TL;DR: In patients with type 2 diabetes mellitus and high cardiovascular risk, there was no significant difference in the risk of cerebrovascular events with empagliflozin versus placebo.
Journal ArticleDOI
Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M Jackson,Pooja Dewan,Inder S. Anand,Jan Bělohlávek,Olof Bengtsson,Rudolf A. de Boer,Michael Böhm,David W. Boulton,Vijay K. Chopra,David L. DeMets,Kieran F. Docherty,Andrej Dukát,Peter J. Greasley,Jonathan G. Howlett,Silvio E. Inzucchi,Tzvetana Katova,Lars Køber,Mikhail Kosiborod,Anna Maria Langkilde,Daniel Lindholm,Charlotta Ljungman,Felipe Martinez,Eileen O'Meara,Marc S. Sabatine,Mikaela Sjöstrand,Scott D. Solomon,Tereshchenko Sn,Subodh Verma,Pardeep S. Jhund,John J.V. McMurray +29 more
TL;DR: The efficacy and safety of dapagliflozin were consistent across the diuretic subgroups examined in DAPA-HF, and mean diurtic dose did not differ between the dAPaglif Lozin and placebo groups after randomization.
Journal ArticleDOI
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Silvio E. Inzucchi,Mikhail Kosiborod,David Fitchett,Christoph Wanner,Uwe Hehnke,Stefan Kaspers,Jyothis T. George,Bernard Zinman +7 more
TL;DR: The objective is to establish a baseline level of consistency in the experimental procedure and establish a procedure for estimating the intensity of the response of the immune system to natural disasters.